Bristol Myers Squibb at #ASH23 (Max Gelman for Endpoints News)

Bris­tol My­ers and 2sev­en­ty bio's Abec­ma sur­vival da­ta raise ques­tions ahead of FDA’s ad­vi­so­ry com­mit­tee meet­ing: #ASH23

SAN DIEGO — The FDA in No­vem­ber de­layed its de­ci­sion on whether to ap­prove Bris­tol My­ers Squibb and 2sev­en­ty bio’s CAR-T cell ther­a­py for ear­li­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.